A combined Phase I/II safety and feasibility trial of MDG1011, in patients with advanced hematological diseases: acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

Trial Profile

A combined Phase I/II safety and feasibility trial of MDG1011, in patients with advanced hematological diseases: acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs MDG 1011 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors MediGene AG
  • Most Recent Events

    • 10 Jul 2017 According to a MediGene AG media release, clinical trial authorization application (CTA) has submitted to the German authority Paul-Ehrlich-Institute (PEI).The final study design will be made available after CTA approval by PEI.
    • 27 Mar 2017 New trial record
    • 23 Mar 2017 According to a MediGene AG media release, this trial is expected to initiate in late 2017, subjects to regulatory approval. Final details of this trial, including trial size, study sites and timelines will become available after clinical trial approval by the competent authority.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top